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Permethrin, a broad-spectrum synthetic pyre-
throid insecticide registered with the U.S. 
Environmental Protection Agency (EPA), 
was first synthesized in 1973 and first mar-
keted in 1977 (Swaine and Tandy 1984). 
Permethrin was first registered and tolerances 
were established in the United States in 1979 
(U.S. EPA 2006). It is widely used agricultur-
ally on cotton, wheat, corn, alfalfa, and other 
crops, and approximately 2 million pounds 
of permethrin are applied annually to agricul-
tural, residential, and public health use sites 
(U.S. EPA 2006), with > 100 million appli-
cations made annually in and around U.S. 
homes (Whitmore et al. 1992). Applications 
in the public health arena have focused par-
ticularly on insect control in buildings and 
aircrafts, treatment of mosquito nets, and 
control of human lice (used in lice shampoos 
and body lotions for scabies) [International 
Agency for Research on Cancer (IARC) 1991; 
National Pesticide Telecommunications 
Network 1997]. In addition, permethrin is 
part of the U.S. Department of Defense’s 
Insect Repellent System (U.S. Department of 
Defense 2002; Young and Evans 1998). It is 
the insecticide used on battle dress uniforms 
(BDUs), because it is considered the most 
effective clothing impregnant available (U.S. 
Department of Defense 2002). Permethrin is 
available in dusts, emulsifiable concentrates, 
smokes, ultra-low-volume concentrates, and 
wettable-powder formulations. Exposure can 
occur via inhalation and dermal contact, and 
at much lower levels from consumption of 
food containing residues (Agency for Toxic 
Substances and Disease Registry 2003; Food 
and Drug Administration 2004). Permethrin, 
like other pyrethroids, works by quickly 
paralyzing the nervous system of insects. It 
kills insects by contact or by ingestion; it 
also has repellent effects (National Pesticide 
Telecommunications Network 1997).
Despite the potential for exposure to 
applicators during permethrin use and pos-
sible exposure to a large proportion of the 
general population from widespread use, 
information is limited concerning its poten-
tial carcinogenicity and mutagenicity. 
Mammalian and nonmammalian bioassays 
and toxicology studies have found potential 
liver carcinogenicity (Hakoi et al. 1992; Price 
et al. 2007), benign lung tumors in female 
mice (Ishmael and Lithfield 1988), lympho-
cyte DNA damage (Gabbianelli et al. 2004), 
endocrine disruption (Chen et al. 2002; Go 
et al. 1999; Kakko et al. 2004; Kim et al. 
2004, 2005), genotoxicity (Tisch et al. 2002), 
and inhibition of gap-junctional intercel-
lular communications (Tateno et al. 1993). 
The U.S. EPA classifies permethrin (CAS no. 
52645-53-1) as a “likely to be carcinogenic 
to humans” (U.S. EPA 2007), based on find-
ings of increased incidence of benign lung 
tumors in female mice (Ishmael and Lithfield 
1988) and liver tumors in rats (Hakoi et al. 
1992) and male and female mice (Ishmael 
and Lithfield 1988). However, the IARC cat-
egorizes permethrin in group 3: not classifi-
able as to carcinogenicity to humans (IARC 
1991). Molecular mechanisms that have been 
proposed for carcinogenicity are a reduction 
in the activity of an enzyme involved in the 
breakdown of the amino acid tryptophan, 
which in turn can lead to buildup of carci-
nogenic tryptophan breakdown products 
(el-Toukhy et al. 1989) and inhibition of 
gap-junctional intercellular communication 
(Tateno et al. 1993), that is, chemical com-
munication between cells, an important step 
in carcinogenesis (Leithe et al. 2006).
To date, the Agricultural Health Study 
(AHS) is the only study to provide informa-
tion on human cancer from exposure to per-
methrin and pyrethroid products (Alavanja 
et al. 2003, 2004; Lee et al. 2007). Because 
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Ba c k g r o u n d: Permethrin is a synthetic pyrethroid insecticide widely used in agriculture, in public 
health, and in many U.S. homes and gardens. 
oB j e c t i v e: In this study we evaluated the incidence of cancer among pesticide applicators exposed 
to permethrin in the Agricultural Health Study (AHS). 
Me t h o d s : A total of 49,093 pesticide applicators were included in this analysis of the AHS, a 
prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. Detailed 
information on pesticide exposure and lifestyle factors was obtained from self-administered ques-
tionnaires completed in 1993–1997. Average length of follow-up since applicator enrollment in the 
cohort was 9.14 years. We used two permethrin exposure metrics: a) lifetime days applicators per-
sonally mixed or applied permethrin and b) intensity-weighted lifetime days (lifetime days weighted 
by estimated intensity of exposure). We used Poisson regression analysis to estimate relative risks 
(RRs) and 95% confidence intervals (CIs) for malignancies by tertiles of exposure. 
re s u l t s: We found no associations between permethrin and all malignant neoplasms combined, 
or between permethrin and melanoma, non-Hodgkin lymphoma, leukemia, or cancers of the 
colon, rectum, lung, or prostate. We found elevated and statistically significant risks for multiple 
myeloma in the highest tertiles of both lifetime exposure-days (RR = 5.72; 95% CI, 2.76–11.87) 
and intensity-weighted lifetime exposure-days (RR = 5.01; 95% CI, 2.41–10.42), compared with 
applicators reporting they never used permethrin; these results are based on only 15 exposed cases. 
These findings were similar across a variety of alternative exposure metrics, exposure categories, and 
reference groups. 
co n c l u s i o n s: This study found no association with most cancers analyzed. Although the 
  suggested association with multiple myeloma was based on a small number of cases, it warrants 
further evaluation.
key w o r d s : agriculture, cancer, multiple myeloma, occupation, permethrin, pesticide applicator, 
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the AHS questionnaire did not explicitly dis-
tinguish products, we refer to “permethrin” 
throughout this article to represent both per-
methrin and pyrethroid products. Permethrin 
has been evaluated for cancer risk in case–
control analyses of AHS data for cancers 
of the prostate (Alavanja et al. 2003), lung 
(Alavanja et al. 2004), colon (Lee et al. 2007), 
and breast (Engel et al. 2005). A positive asso-
ciation for prostate cancer was found among 
applicators with a family history of prostate 
cancer who ever reported applying permethrin 
to animals [relative risk (RR) = 2.38; 95% 
confidence interval (CI), 1.34–4.25], but not 
among applicators without a family history 
of prostate cancer (Alavanja et al. 2003). No 
associations were found with permethrin used 
on crops (Alavanja et al. 2003), and no asso-
ciations were found between lung cancer or 
colon cancer and animal or crop permethrin 
use (Alavanja et al. 2004; Lee et al. 2007). 
There was no association between permethrin 
use and risk of breast cancer among farmers’ 
wives in the AHS (Engel et al. 2005).
For the present analysis, we investigated 
site-specific cancer incidence and risk among 
pesticide applicators exposed to permethrin in 
the AHS cohort to provide additional infor-
mation on this important agricultural chemi-
cal. Given the increased follow-up time for 
case accrual, in this study we extend previous 
analyses for prostate, lung, and colon cancers 
(Alavanja et al. 2003, 2004; Lee et al. 2007) 
and examine the relationship between per-
methrin and additional cancer sites.
Materials and Methods
Cohort enrollment and follow-up. The AHS 
is a prospective cohort study composed of 
57,311 private and commercial applicators 
who were licensed to apply restricted-use pes-
ticides in Iowa or North Carolina at the time 
of enrollment (82.4% of eligible applicators 
in both states enrolled) (Blair et al. 1992). 
Recruitment of the cohort occurred between 
1993 and 1997 (Alavanja et al. 1996). Cohort 
members were matched to cancer registry files 
in Iowa and North Carolina for case identi-
fication and to the state death registries and 
the National Death Index to ascertain vital 
status. For this analysis, we identified inci-
dent cancers between date of enrollment and 
31 December 2004 and coded them according 
to the International Classification of Diseases 
for Oncology, 2nd Revision (ICD-O-2) (World 
Health Organization 1990). We identi-
fied cohort members no longer residing in 
Iowa or North Carolina (n = 978) through 
current address searches by the Internal 
Revenue Service (address information only), 
motor vehicle registration offices, and pes-
ticide license registries of the state agricul-
tural departments and censored them in the 
year that they left the state. Individuals were 
followed until the earliest of first primary can-
cer diagnosis of any type, death, date they left 
the state, or 31 December 2004. The average 
time of follow-up from enrollment was 9.14 
years. All participants provided informed con-
sent, and the institutional review boards of the 
National Cancer Institute (Bethesda, MD), 
Battelle Centers for Public Health Research 
and Evaluation (Durham, NC) (field station 
in North Carolina), University of Iowa (field 
station in Iowa), and Westat, Inc. (Rockville, 
MD) (coordinating center for the study) 
approved the protocol.
Exposure assessment. A self-administered 
enrollment questionnaire collected compre-
hensive exposure data on 22 pesticides; ever/
never-use information for 28 additional pesti-
cides; information on use of personal protec-
tive equipment (PPE), pesticide application 
methods, pesticide mixing, pesticide equip-
ment repair, smoking, alcohol consumption, 
and cancer history of first degree relatives; and 
basic demographic data (Alavanja et al. 1999). 
Reliability of pesticide reporting has been 
evaluated, and percentage agreement is in the 
70–90% range for ever/never use of individual 
pesticides and in the 50–60% range for dura-
tion, frequency, and decade of use (Blair et al. 
2002). The questionnaire may be accessed 
online (National Institutes of Health 2008).
In the AHS, two types of permethrin expo-
sure were assessed: permethrin used on ani-
mals and permethrin or pyrethroid products 
used on crops. Because these two uses have 
a similar mix of compounds, for this study 
we combined data for both permethrin uses, 
constructed two lifetime permethrin exposure 
metrics (lifetime exposure-days and intensity-
weighted lifetime exposure-days), and catego-
rized each into tertiles. We based the lifetime 
exposure-days metric on the number of years 
an applicator personally applied or mixed per-
methrin multiplied by the number of days in 
an average year an applicator personally mixed 
or applied permethrin. We used the midpoints 
of the questionnaire categories to calculate the 
product of years of use times days per year. We 
summed the lifetime exposure-days for animal-
use permethrin and for crop-use permethrin 
to yield our permethrin lifetime days metric 
(  tertiles: < 8.75, 8.75–50.75, > 50.75 days).
The intensity-weighted lifetime expo-
sure-days metric was the product of lifetime 
exposure-days and intensity level, which 
incorporates factors that may influence the 
extent of exposure during pesticide mixing 
and application. We used enrollment ques-
tionnaire data in an algorithm to estimate 
intensity of exposure to individual pesticides 
as follows: intensity level = [(mixing status + 
application method + equipment repair sta-
tus) × PPE use] (Dosemeci et al. 2002). We 
assigned the scores to each factor in the inten-
sity-level algorithm not as nominal or ordinal 
values, but as weighted values to reflect likely 
intensity of exposure (to pesticides, not to 
permethrin specifically), as described in the 
literature (Dosemeci et al. 2002). Mixing sta-
tus was a three-level variable based on never 
mixing, personally mixing < 50% of the time, 
and personally mixing ≥ 50% of the time 
(mixing status = 0, 3, and 9, respectively). 
Application method was a six-level variable 
based on never applying, use of aerial aircraft 
or distribution of tablets, application in fur-
row, use of boom on tractor, use of backpack, 
and use of hand spray (application method 
= 0, 1, 2, 3, 8, 9, respectively). Equipment 
repair status was a two-level variable based on 
not repairing or repairing (equipment repair 
status = 0, 2, respectively). PPE use was an 
eight-level variable based on type of PPE used 
while applying pesticides. We combined life-
time exposure-days with the measure of inten-
sity (a scored value ranging from 0.2 to 20.0) 
to create intensity-weighted lifetime exposure-
days. We summed intensity-weighted lifetime 
exposure-days for animal-use and crop-use 
permethrin to yield our permethrin inten-
sity-weighted lifetime exposure-days metric 
(tertiles: < 59.5, 59.5–220.5, > 220.5 inten-
sity-weighted lifetime exposure-days). 
Statistical analysis. We excluded from 
this analysis individuals with prevalent can-
cers (i.e., those diagnosed before enrollment; 
n = 1,084), who did not provide information 
on permethrin use (n = 6,855), or with miss-
ing information on age or person-years of 
follow-up (n = 278), leaving 49,093 applica-
tors included in the analyses. Analyses of first 
primary incident cancer cases enabled us to 
obtain exposure data from each case before 
the onset of cancer.
We fit Poisson regression models for indi-
vidual cancer sites to estimate RRs associ-
ated with tertiles of lifetime exposure-days 
or intensity-weighted exposure-days. We 
investigated all cancer sites classified under 
ICD-O-2, but present results only for cancers 
for which there were at least 15 permethrin-
exposed cases, after accounting for missing 
covariate data. Cancer sites meeting this cri-
terion included all cancers combined; can-
cers of the colon, rectum, lung, prostate, and 
bladder; melanoma; all lymphohematopoietic 
system cancers; leukemia; multiple myeloma; 
and non-Hodgkin lymphoma. We adjusted 
rate ratios for age at enrollment (< 40, 40–49, 
50–59, ≥ 60), sex, race (white, nonwhite), 
family history in first-degree relative of the 
specific cancer being analyzed (yes, no), ciga-
rette smoking (never/low/high: we used the 
median value of pack-years among smokers to 
classify low and high categories of smokers), 
state of residence (Iowa/North Carolina), and 
enrollment year. Because of potential concom-
itant exposure to other pesticides, we inves-
tigated the correlations between permethrin Cancer in pesticide applicators exposed to permethrin
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use and use of other pesticides. We calculated 
Spearman correlation coefficients (r) for life-
time days and for intensity-weighted lifetime 
exposure-days of permethrin with all other 
pesticides in the AHS. For lifetime exposure-
days, the five pesticides most highly correlated 
with permethrin were trichlorfon (r = 0.35), 
ziram (r = 0.24), coumaphos (r = 0.19), chlo-
rothalonil (r = 0.19), and aldicarb (r = 0.18); 
for intensity-weighted lifetime exposure-days, 
the five most highly correlated pesticides were 
dichlorvos (r = 0.25), cyanazine (r = 0.24), 
metolachlor (r = 0.22), atrazine (r = 0.22), 
and alachlor (r = 0.22) Because these cor-
relation coefficients were small, we consid-
ered whether they should be included in the 
final models by first including them and then 
removing them from the models for lifetime 
exposure-days and intensity-weighted life-
time exposure-days. We analyzed exposure–
response trends by including the midpoint 
of each tertile as a continuous variable in the 
model and testing for the statistical signifi-
cance of the slope.
To evaluate the more appropriate refer-
ence group for RRs—applicators who never 
applied permethrin (hereafter referred to as 
“non-permethrin-exposed applicators”) or 
applicators in the lowest exposure tertile of 
permethrin, we compared baseline charac-
teristics of each of these groups with those of 
applicators with permethrin exposure in the 
highest tertiles (for lifetime exposure-days). 
We considered applicators with baseline char-
acteristics more similar to those of the applica-
tors in the higher exposure group to be more 
appropriate as referents for the Poisson regres-
sion analyses, because differences with respect 
to baseline characteristics (Table 1) might 
introduce residual confounding from a variety 
of unidentified sources.
We carried out additional analyses on pros-
tate cancer to compare our results with those of 
the nested case–control analysis of prostate can-
cer in the AHS (Alavanja et al. 2003). For these 
analyses, we stratified by family history of pros-
tate cancer, compared applicators ever exposed 
to permethrin with those never exposed, and 
calculated an interaction RR.
We conducted all statistical analyses with 
Stata (version 9.0; StataCorp, College Station, 
TX). We used the P1REL0612 release of the 
AHS database (www.aghealth.org).
Results
Table 1 presents selected characteristics of 
the permethrin-exposed and non-permethrin-
exposed applicators, categorized by lifetime 
exposure-days [nonexposed, lower exposed 
(lowest tertile), and higher exposed (top two 
tertiles combined)]. Among 49,093 subjects 
with complete exposure information, 11,623 
(24%) reported ever having personally applied 
or mixed permethrin and had complete data 
on lifetime days of use. The cohort, both 
exposed and nonexposed, consisted primarily 
of white, male private applicators. This is a 
population with relatively low smoking rates; 
about half of the applicators reported that 
they had never smoked. Because there were no 
pronounced or consistent differences across 
the three groups for baseline characteristics, 
we determined that either the nonexposed 
applicators or the applicators in the lowest 
tertile of exposure would be a reasonable 
reference group, but they have slightly dif-
ferent assumptions. Although we carried out 
analyses using both reference groups, we pres-
ent only RRs based on the nonexposed group 
in Table 2.
Table 2 presents the Poisson regression 
RRs of selected cancers with tertiles of expo-
sure to permethrin, for lifetime days and for 
intensity-weighted lifetime exposure-days. 
Including the most highly correlated pesti-
cides in the final models did not appreciably 
Table 1. Characteristics of study participants in permethrin chemical-specific analyses [no. (%)].
   Lowest exposed  Two highest
  Nonexposed  tertile lifetime  tertiles lifetime
Characteristic   (n = 37,470)   days (n = 4,325)  days (n = 7,298)
Age (years)
  < 40  12,099 (32.3)  1,593 (36.8)  2,853 (39.1)
  40–49  10,179 (27.2)  1,418 (32.79)  2,506 (34.3)
  50–59  7,852 (21.0)  847 (19.6)  1,262 (17.3)
  ≥ 60  7,340 (19.6)  467 (10.8)  677 (9.3)
Sex 
  Males  36,399 (97.1)  4,257 (98.4)  7,167 (98.2)
  Females  1,071 (2.9)  68 (1.6)  131 (1.8)
Race     
  White  36,455 (97.3)  4,276 (98.9)  7,190 (98.5)
  Other  929 (2.5)  38 (0.9)  92 (1.3)
  Missing  96 (0.3)  11 (0.3)  16 (0.2)
Residence     
  Iowa  24,896 (66.4)  3,442 (79.6)  5,000 (68.5)
  North Carolina  12,574 (33.6)  883 (20.4)  2,298 (31.5)
Applicator     
  Commercial  3,284 (8.8)  297 (6.9)  872 (12.0)
  Private  34,186 (91.2)  4,028 (93.13)  6,426 (88.1)
Smoking (pack-years)     
  0  19,613 (52.3)  2,513 (58.1)  4,082 (55.9)
  < 12  8,227 (22.0)  947 (21.9)  1,579 (21.6)
  12–195  8,291 (22.1)  770 (17.8)  1,453 (19.9)
  Missing  1,339 (3.6)  95 (2.2)  184 (2.5)
Alcohol frequency per year (no. of drinks)     
  0  12,217 (32.6)  1,008 (23.3)  1,771 (24.3)
  ≤ 30  24,721 (66.0)  3,278 (75.8)  5,433 (74.5)
  Missing  532 (1.4)  39 (0.9)  94 (1.3)
Education     
  ≤ High school equivalent  21,437 (57.2)  1,951 (45.1)  3,237 (44.4)
  > High school  15,242 (40.7)  2,316 (53.6)  3,920 (53.7)
  Missing  791 (2.1)  58 (1.3)  141 (1.9)
Cancer history (first-degree relative)     
  No  21,372 (57.0)  2,390 (55.3)  3,968 (54.4)
  Yes  13,848 (36.96)  1,763 (40.8)  2,975 (40.8)
  Missing  2,250 (6.0)  172 (4.0)  355 (4.9)
Trichlorfon use      
  Ever  295 (0.8)  35 (0.8)  168 (2.3)
  Never  36,928 (98.6)  4,154 (96.1)  6,831 (93.6)
  Missing  247 (0.7)  136 (3.1)  299 (4.1)
Ziram use     
  Ever  49 (0.1)  16 (0.4)  42 (0.6)
  Never  16,286 (43.5)  1,956 (45.2)  3,013 (41.3)
  Missing  21,135 (56.4)  2,353 (54.4)  4,243 (58.1)
Coumaphos use      
  Ever  2,053 (5.5)  541 (12.5)  1,140 (15.6)
  Never  34,918 (93.2)  3,605 (83.4)  5,831 (79.9)
  Missing  499 (1.3)  179 (4.1)  327 (4.5)
Chlorothalonil use     
  Ever  2,413 (6.4)  405 (9.36)  1,307 (17.9)
  Never  34,935 (93.2)  3,885 (89.8)  5,935 (81.3)
  Missing  122 (0.3)  35 (0.8)  56 (0.8)
Aldicarb use     
  Ever  1,017 (2.7)  158 (3.7)  448 (6.1)
  Never  15,257 (40.7)  1,808 (41.8)  2,621 (35.9)
  Missing  21,196 (56.6)  2,359 (54.5)  4,229 (58.0)Rusiecki et al.
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change the estimates, so we opted for a more 
parsimonious model. We observed no sig-
nificant variation in RRs for all cancers com-
bined, bladder cancer, colon cancer, lung 
cancer, melanoma, non-Hodgkin lymphoma, 
prostate cancer, and rectum cancer, although 
for rectum and lung cancers and melanoma 
RRs tended to be small among the more 
heavily exposed applicators. For all lympho-
hematopoietic cancers combined, there was a 
statistically significant increased risk in the top 
tertile of permethrin lifetime exposure-days 
(RR = 1.64; 95% CI, 1.07–2.52), but the test 
for trend was not statistically significant (p = 
0.35). The RR estimate for the top tertile of 
permethrin intensity-weighted lifetime expo-
sure-days was elevated but not statistically 
significant for all lymphohematopoietic can-
cers (RR = 1.31; 95% CI 0.84–2.04; p-trend 
= 0.60). We found a similar pattern for leu-
kemia (a lymphohematopoietic cancer), in 
that the lifetime exposure-days estimate was 
elevated but not statistically significant (RR 
= 1.74; 95% CI, 0.83–3.64; p-trend = 0.60) 
and the RR for the intensity-weighted lifetime 
exposure-days metric was smaller (RR = 1.34; 
95% CI, 0.61–2.92; p-trend = 0.95). We 
found an elevated risk for multiple myeloma 
among applicators in the highest tertile (n = 
10) of lifetime exposure-days compared with 
nonexposed applicators (RR = 5.72; 95% CI, 
2.76–11.87); the p-trend was statistically sig-
nificant (< 0.01), but the RRs did not increase 
monotonically. We also found an elevation 
of risk for the highest tertile of intensity-
weighted lifetime exposure-days metric (RR 
= 5.01; 95% CI, 2.41–10.42; p-trend < 0.01). 
Compared with the lowest exposed group, 
we found statistically significant, elevated 
RRs in the upper tertile of exposure both for 
lifetime exposure-days (RR = 4.76; 95% CI, 
1.29–17.52; p-trend = 0.01) and for intensity-
weighted lifetime exposure-days (RR = 5.32; 
95% CI, 1.15–24.54; p-trend = 0.02; data 
not shown). For all cancers combined and for 
other individual cancers, results were simi-
lar when the referent was the lowest exposed 
group (data not shown).
Among applicators with a family history of 
prostate cancer, we found little evidence of an 
association with use of permethrin when com-
paring those ever exposed with those never 
exposed (RR = 1.19; 95% CI, 0.82–1.3). 
Those without a family history showed a slight 
deficit (RR = 0.88; 95% CI, 0.72–1.07). The 
interaction term was statistically significant 
(RR = 1.61; 95% CI, 1.08–2.40).
We also carried out all our Poisson regres-
sion analyses on animal-use permethrin and 
crop-use permethrin separately (data not 
shown) for both lifetime exposure-days and 
intensity-weighted lifetime exposure-days, 
using the two reference groups; results in both 
groups were similar to those for the combined 
permethrin results.
Discussion
We found no association between permethrin 
and all cancers combined; cancers of the 
colon, rectum, lung, prostate, and bladder; 
melanoma; and non-Hodgkin lymphoma. 
Some RR estimates for all lymphohematopoi-
etic cancers and for leukemia were elevated 
(lifetime days), but findings were not consis-
tent across exposure metrics. We found an 
elevated risk for multiple myeloma among 
applicators in the highest tertile (n = 10) of 
lifetime exposure-days (RR = 5.72; 95% CI, 
2.76–11.87; p-trend < 0.01) and in the high-
est tertile of intensity-weighted lifetime expo-
sure-days (RR = 5.01; 95% CI, 2.41–10.42; 
p-trend < 0.01) compared with nonexposed 
applicators. We also found consistently ele-
vated and statistically significant risks for mul-
tiple myeloma for both exposure metrics and 
when using applicators in the lowest tertile 
of exposure as the reference group. However, 
there were only 15 exposed cases; small num-
bers indicate this could be a chance finding.
To  further  evaluate  the  multiple 
myeloma association, we carried out a series 
of additional analyses using different catego-
rizations of lifetime exposure-days and inten-
sity-weighted lifetime exposure-days, as well 
as other exposure metrics available to us in the 
AHS: years applied permethrin, average days 
per year applied permethrin, and intensity 
score for permethrin. We found consistently 
Table 2. Rate ratios and 95% CIsa for selected cancers with permethrin exposure, comparing each tertile 
of exposure with nonexposed applicators. 
    Intensity-weighted 
  Lifetime exposure-days  lifetime exposure-days
Cancer (ICD-O-2 code)  Tertileb  No.  RR (95% CI)  p-Trend  No.  RR (95% CI)  p-Trend
All malignant neoplasms  0  2,059  1.00 (referent)    2,059  1.00 (referent)
  (codes 140–208)  1  171  0.92 (0.79–1.08)    141  0.83 (0.70–0.99)
  2  128  0.84 (0.70–1.00)    142  0.98 (0.82–1.16)
  3  129  0.94 (0.79–1.12)  0.09  142  0.90 (0.75–1.06)  0.12
Colon (code 153)  0  155  1.00 (referent)    155  1.00 (referent)
  1  13  0.96 (0.54–1.69)    11  0.89 (0.48–1.64)
  2  7  0.63 (0.30–1.35)    10  0.94 (0.49–1.78)
  3  13  1.32 (0.75–2.34)  0.91  12  1.07 (0.59–1.93)  1.00
Rectum (code 154)  0  87  1.00 (referent)    87  1.00 (referent)
  1  7  0.85 (0.39–1.85)    6  0.81 (0.35–1.86)
  2  4  0.58 (0.21–1.59)    5  0.77 (0.31–1.90)
  3  5  0.78 (0.31–1.92)  0.29  5  0.67 (0.27–1.65)  0.28
Lung (code 162)  0  204  1.00 (referent)    204  1.00 (referent)
  1  13  0.85 (0.49–1.50)    14  1.01 (0.59–1.74)
  2  8  0.60 (0.30–1.22)    7  0.58 (0.27–1.24)
  3  9  0.69 (0.35–1.34)  0.09  9  0.57 (0.29–1.12)  0.05
Melanoma (code 172)  0  84  1.00 (referent)    84  1.00 (referent)
  1  9  1.01 (0.50–2.01)    7  0.85 (0.39–1.85)
  2  6  0.79 (0.35–1.83)    6  0.84 (0.37–1.93)
  3  0   —  0.02  2  0.25 (0.06–1.01)  0.05
Prostate (code 185)  0  853  1.00 (referent)    853  1.00 (referent)
  1  82  1.11 (0.89–1.40)    60  0.89 (0.68–1.16)
  2  53  0.89 (0.68–1.18)    69  1.20 (0.94–1.53)
  3  44  0.87 (0.64–1.18)  0.37  50  0.87 (0.65–1.16)  0.83
Bladder (code 188)  0  97  1.00 (referent)    97  1.00 (referent)
  1  6  0.74 (0.32–1.70)    6  0.83 (0.36–1.89)
  2  3  0.46 (0.15–1.46)    4  0.64 (0.24–1.75)
  3  8  1.33 (0.64–2.74)  0.82  7  1.00 (0.46–2.15)  0.61
All lymphohematopoietic  0  207  1.00 (referent)    207  1.00 (referent)
  cancers (codes 200–208)  1  17  0.85 (0.51–1.39)    15  0.83 (0.49–1.40)
  2  10  0.61 (0.32–1.16)    13  0.83 (0.47–1.46)
  3  24  1.64 (1.07–2.52)  0.35  22  1.31 (0.84–2.04)  0.60
Non-Hodgkin lymphoma   0  94  1.00 (referent)    94  1.00 (referent)
  (codes 200–202)  1  8  0.84 (0.41–1.74)    7  0.81 (0.38–1.76)
  2  5  0.64 (0.26–1.68)    7  0.94 (0.43–2.02)
  3  5  0.69 (0.28–1.71)  0.22  4  0.48 (0.18–1.31)  0.18
Multiple myeloma  0  29  1.00 (referent)    29  1.00 (referent) 
  (code 203)  1  3  1.21 (0.37–3.99)    2  0.92 (0.22–3.85) 
  2  2  1.02 (0.24–4.31)    3  1.55 (0.47–5.12) 
  3  10  5.72 (2.76–11.87)   < 0.01  10  5.01 (2.41–10.42)   < 0.01
Leukemia  0  72  1.00 (referent)    72  1.00 (referent)
  (code 204–208)  1  5  0.75 (0.30–1.87)    5  0.83 (0.33–2.06)
  2  3  0.56 (0.18–1.78)    3  0.58 (0.18–1.86)
   3  8  1.74 (0.83–3.64)  0.60  7  1.34 (0.61–2.92)  0.95
aAdjusted for age, sex, race, family history of cancer, cigarette smoking, state of residence, and enrollment year. bLifetime 
days tertiles: 0, never exposed; 1, ≤ 8.75; 2, 8.74–50.75; 3 > 50.75; intensity-weighted lifetime days tertiles: 0, never exposed; 
1, < 59.5; 2, 59.5–220.5; 3 ≥ 220.5.Cancer in pesticide applicators exposed to permethrin
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elevated RRs in the top exposure categories 
and highly significant tests for trend (data 
not shown). An analysis stratifying by state of 
residence showed statistically significant eleva-
tions in the upper tertile for both Iowa and 
North Carolina (data not shown).
Human data on cancer and permethrin 
exposure are limited. The only epidemiologic 
findings available, based on earlier analyses in 
the AHS cohort, showed an elevated risk for 
prostate cancer among applicators with a family 
history of prostate cancer who ever applied per-
methrin to animals (RR = 2.38; 95% CI, 1.34–
4.25), compared with those who never applied 
it, but no elevation among applicators who had 
no family history of prostate cancer (Alavanja 
et al. 2003). Our results for prostate cancer 
were weaker. The reasons for this difference are 
not clear. Our cohort analysis consisted of five 
additional years of cancer incidence data and 
was based on a combined use of permethrin 
on animals and on crops, whereas the analysis 
by Alavanja et al. (2003) was a case–control 
analysis based on the use of permethrin on 
animals. However, in an analysis for animal 
permethrin alone, we found no strong associa-
tion. Other case–control analyses in the AHS 
found no evidence of elevated risk for cancer 
of the lung (Alavanja et al. 2004), colon (Lee 
et al. 2007), or breast (Engel et al. 2005) with 
permethrin exposure; we also found no evi-
dence of elevated risk for these cancers in this 
analysis. Chemical-specific analyses from the 
AHS have shown non-statistically significant 
increases in multiple myeloma with glyphosate 
use (De Roos et al. 2005) and atrazine use 
(Rusiecki et al. 2004). However, adjustment 
for atrazine, glyphosate, and other highly cor-
related pesticides did not affect the results, so 
the association between multiple myeloma and 
permethrin observed here is unlikely to be due 
to confounding by other pesticide exposures.
Before introducing permethrin-impreg-
nated BDUs for military personnel, the U.S. 
Army asked the National Research Council 
(NRC) to review the toxicologic and exposure 
data on permethrin and perform a quantita-
tive risk assessment to evaluate health risks to 
deployed U.S. military personnel from vector 
management tactics. The NRC risk assess-
ment was used to determine whether wear-
ing BDUs impregnated with permethrin (at a 
concentration of 0.125 mg/cm2 of fabric) 18 
hr/day, 7 days/week, for up to 10 years is safe 
for soldiers, and whether handling permethrin-
impregnated fabric is safe for garment work-
ers. The aggregate cancer risk for permethrin, 
based on estimated exposures for various sce-
narios and pathways, was found to be low 
(Macedo et al. 2007). The NRC concluded 
that, based on the review of toxicity data on 
permethrin, soldiers who wear permethrin-
impregnated BDUs are unlikely to experience 
adverse health effects (NRC 1994).
There are no previous human data on a 
potential link between permethrin exposure 
and multiple myeloma. Multiple myeloma is 
an incurable B-cell malignancy morphologi-
cally characterized by a proliferation of plasma 
cells in the bone marrow (Kyle and Rajkumar 
2004). It is often preceded by a clinically 
benign and typically asymptomatic precur-
sor condition, monoclonal gammopathy of 
undetermined significance (MGUS) (Kyle 
et al. 2002; Landgren et al. 2006). However, 
it remains unclear whether MGUS precedes 
all cases of multiple myeloma, or if multiple 
myeloma can arise de novo without preced-
ing MGUS (Hideshima et al. 2007). To date, 
there are no established lifestyle, occupational, 
or environmental risk factors for MGUS and 
multiple myeloma (Landgren and Kyle 2007). 
Because the risk of progression from MGUS 
to multiple myeloma in the general population 
has been reported to be very stable regardless 
of the duration of antecedent MGUS (Kyle 
et al. 2002; Landgren et al. 2006), it has been 
proposed to reflect the second hit in a ran-
dom, two-hit genetic model of malignancy 
(Rajkumar 2005). The specific second hit that 
initiates the cascade of events associated with 
progression is unknown but may include gene–
environment interactions. Permethrin might 
play a role as an immune modulatory factor 
(via immune stimulation, immune dysregula-
tion, or both) involved in multiple myeloma 
progression. Alternatively, permethrin might 
act in a similar fashion and trigger the devel-
opment of MGUS, which in turn is reflected 
in an excess risk of multiple myeloma, or the 
observed elevated risk of multiple myeloma 
could simply be a chance finding.
A hypothesis proposed for the potential car-
cinogenicity of permethrin involves the break-
down of an amino acid, tryptophan, which 
can in turn lead to buildup of carcinogenic 
tryptophan breakdown products (el-Toukhy 
et al. 1989) and inhibition of gap-junctional 
intercellular communication (Tateno et al. 
1993). Mechanisms of action, however, are 
often dose dependent, and because the AHS 
does not include dose information, our discus-
sion of mechanisms and biological plausibility 
must be limited at this time. In experimental 
studies, permethrin has been evaluated for car-
cinogenic activity in both rats and mice and for 
mutagenic activity in vitro. Results of cancer 
bioassays in laboratory animals are mixed, and 
none have indicated an increased risk for mul-
tiple myeloma or other hematopoietic cancers 
(el-Toukhy et al. 1989; Gabbianelli et al. 2004; 
Hakoi et al. 1992; IARC 1991; Ishmael and 
Lithfield 1988; Tisch et al. 2002).
Certain limitations of our data hinder 
the inferences we can make regarding can-
cer risks from permethrin use. Although the 
AHS cohort is large, and 11,688 participants 
reported permethrin use, the small numbers of 
certain cancers occurring during the 9.14-year 
average follow-up period resulted in relatively 
imprecise risk estimates. In addition, most per-
methrin applicators were male (98%), preclud-
ing our ability to assess the association between 
permethrin exposure and female cancers. 
Another limitation is that almost all applica-
tors identified themselves as white (99%). Our 
analysis provides limited information on the 
timing of pesticide use in relation to disease. 
Additionally, with only 9.14 years of follow-
up, we are limited in our conclusions concern-
ing latency and temporal changes in PPE. We 
will better address these issues with increased 
follow-up and exposure data from subsequent 
phases of the AHS. Although our study used 
more detailed exposure estimates than did 
earlier studies, the hours per day applicators 
engaged in pesticide application could vary 
considerably. Finally, although the exposure 
scale in this study is more sophisticated than 
that employed in most epidemiologic studies of 
pesticides, undoubtedly considerable exposure 
misclassification still occurs, which would tend 
to bias risk estimates in a prospective study 
such as this toward the null.
The AHS has several important strengths. 
It is the largest study of pesticide applicators 
exposed to permethrin to date. Exposure 
information was gathered before cancer diag-
nosis, thereby minimizing recall bias. In gen-
eral, farmers provide reliable information and 
considerable detail regarding their pesticide 
application history (Blair and Zahm 1993; 
Blair et al. 1997, 2002; Coble et al. 2002). 
The AHS cohort consists of licensed pesticide 
applicators who are responsible for a thorough 
understanding of pesticide regulations and 
for the purchase and application of chemi-
cals (Hoppin et al. 2002). Recall of pesticide 
use by the AHS cohort has been shown to 
be consistent with the dates these pesticides 
came onto the market (Hoppin et al. 2002). 
Comprehensive questionnaire data was used 
to quantify permethrin exposure levels, pro-
viding discrimination between high and low 
exposures, rather than defining exposure as 
“ever used” permethrin. In addition, detailed 
information on the use of many common pes-
ticides and lifestyle characteristics allowed us 
to adjust for potential confounding factors.
Despite the limitations noted above, our 
prospective study of cancer incidence among 
permethrin-exposed pesticide applicators pro-
vided an opportunity afforded in few other 
studies to evaluate cancer risks associated with 
exposure to this very widely used pesticide, 
while adjusting for lifestyle factors. We found 
no evidence of increased risk of cancer for 
most of the sites we investigated. There was 
a suggestion of an increased risk for multiple 
myeloma with increased lifetime exposure-days 
and intensity-weighted lifetime exposure-days 
and other exposure metrics (average days per Rusiecki et al.
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year, total years, intensity level). However, the 
number of exposed multiple myeloma cases 
was small, and we cannot rule out that these 
findings may have occurred by chance. We 
intend to follow up these results in the future, 
focusing specifically on multiple myeloma as 
more cases develop in the cohort.
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